IL-33 signaling fuels outgrowth and metastasis of human lung cancer

Biochemical and Biophysical Research Communications

Volumn 479, Issue 3, 2016, Pages 461-468

  Wang, Chunhong ^a,b   Chen, Zengsheng ^c   Bu, Xiangmao ^d   Han, Yang ^b   Shan, Shan ^b   Ren, Tao ^b   Song, Weiqing ^a,c  

^a QINGDAO UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c QINGDAO MUNICIPAL HOSPITAL   (China)

^d Qingdao Women Children s Hospital   (China)

Author keywords

GLUT1; IL 33; Lung cancer

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 1; INTERLEUKIN 33; SHORT HAIRPIN RNA; SOMATOSTATIN RECEPTOR 2; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; SLC2A1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CELL STIMULATION; CLINICAL ARTICLE; EXPRESSION VECTOR; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG BIOPSY; METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; DISEASE COURSE; FLOW CYTOMETRY; LUNG TUMOR; METABOLISM;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION;

EID: 84989942380     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.09.081     Document Type: Article

References (32)

1. [1] Hong, Q.Y., Wu, G.M., Qian, G.S., et al. Prevention and management of lung cancer in China. Cancer 121 (2015), 3080–3088.
2. [2] Wood, S.L., Pernemalm, M., Crosbie, P.A., et al. Molecular histology of lung cancer: from targets to treatments. Cancer. Treat. Rev. 41 (2015), 361–375.
3. [3] Zhang, X., Wang, C., Shan, S., et al. TLR4/ROS/miRNA-21 pathway underlies lipopolysaccharide instructed primary tumor outgrowth in lung cancer patients. Oncotarget, 7 Jun 2016, 10.18632/oncotarget.9902 [Epub ahead of print].
4. [4] Hardman, C., Ogg, G., Interleukin-33, friend and foe in type-2 immune responses. Curr. Opin. Immunol. 42 (2016), 16–24.
5. [5] Peine, M., Marek, R.M., Löhning, M., IL-33 in T Cell differentiation, function, and immune homeostasis. Trends. Immunol. 37 (2016), 321–333.
6. [6] Kakkar, R., Lee, R.T., The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug. Discov. 7 (2008), 827–840.
7. [7] Mirchandani, A.S., Salmond, R.J., Liew, F.Y., Interleukin-33 and the function of innate lymphoid cells. Trends. Immunol. 33 (2012), 389–396.
8. [8] Schwartz, C., O'Grady, K., Lavelle, E.C., et al. Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer. Eur. J. Immunol. 46 (2016), 1091–1100.
9. [9] Lu, B., Yang, M., Wang, Q., Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J. Mol. Med. Berl. 94 (2016), 535–543.
10. [10] Naumnik, W., Naumnik, B., Niewiarowska, K., et al. Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer. Exp. Oncol. 34 (2012), 348–353.
11. [11] Hu, L.A., Fu, Y., Zhang, D.N., et al. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian. pac. J. Cancer. Prev. 14 (2013), 2563–2566.
12. [12] Kim, M.S., Kim, E., Heo, J.S., et al. Circulating IL-33 level is associated with the progression of lung cancer. Lung. Cancer 90 (2015), 346–351.
13. [13] Barrera, L., Montes-Servín, E., Barrera, A., et al. Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. Ann. Oncol. 26 (2015), 428–435.
14. [14] Akimoto, M., Hayashi, J.I., Nakae, S., et al. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. Cell. Death. Dis., 7, 2016, e2057.
15. [15] Liu, X., Zhu, L., Lu, X., et al. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem. Biophys. Res. Commun. 453 (2014), 486–492.
16. [16] Li, Q., Han, Y., Wang, C., et al. MicroRNA-125b promotes tumor metastasis through targeting tumor protein 53-induced nuclear protein 1 in patients with non-small-cell lung cancer. Cancer. Cell. Int., 15, 2015, 84.
17. [17] Hattar, K., Savai, R., Subtil, F.S., et al. Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. Cancer. Immunol. Immunother. 62 (2013), 309–320.
18. [18] Yan, L., Cai, Q., Xu, Y., The ubiquitin-CXCR4 axis plays an important role in acute lung infection-enhanced lung tumor metastasis. Clin. Cancer. Res. 19 (2013), 4706–4716.
19. [19] Sun, Q., Chen, X., Ma, J., et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 4129–4134.
20. [20] Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11 (2011), 85–95.
21. [21] Zhang, L., Lu, R., Zhao, G., et al. TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int. J. Biochem. Cell. Biol. 43 (2011), 1383–1391.
22. [22] Polumuri, S.K., Jayakar, G.G., Shirey, K.A., et al. Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J. Immunol. 189 (2012), 50–60.
23. [23] Qi, F., Wang, D., Liu, J., et al. Respiratory macrophages and dendritic cells mediate respiratory syncytial virus-induced IL-33 production in TLR3- or TLR7-dependent manner. Int. Immunopharmacol. 29 (2015), 408–415.
24. [24] Mertz, K.D., Mager, L.F., Wasmer, M.H., et al. The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology, 5, 2015, e1062966.
25. [25] Maywald, R.L., Doerner, S.K., Pastorelli, L., et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E2487–E2496.
26. [26] Zhang, Y., Davis, C., Shah, S., et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol. Carcinog., 27 Apr 2016, 10.1002/mc.22491 [Epub ahead of print].
27. [27] Deng, K., Wang, H., Shan, T., et al. Tristetraprolin inhibits gastric cancer progression through suppression of IL-33. Sci. Rep., 6, 2016, 24505.
28. [28] Yu, X.X., Hu, Z., Shen, X., et al. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig. Dis. Sci. 60 (2015), 1265–1272.
29. [29] Tong, X., Barbour, M., Hou, K., et al. Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. Mol. Oncol. 10 (2016), 113–125.
30. [30] Mager, L.F., Riether, C., Schürch, C.M., et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J. Clin. Investig. 125 (2015), 2579–2591.
31. [31] Sommermann, T.G., O'Neill, K., Plas, D.R., et al. IKKβ and NF-κB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer. Res. 71 (2011), 7291–7300.
32. [32] Liu, J., Zhang, C., Wu, R., et al. RRAD inhibits the Warburg effect through negative regulation of the NF-κB signaling. Oncotarget 6 (2015), 14982–14992.